| You are here: Home: BCU 9|2003 - Supplement : Case 3: From the practice of Gracy Joshua, MD: Select publications
Select publications
Choice of hormonal therapy in the postmenopausal woman
Baum M, Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am 2003;83(4):973-94. Abstract
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9. Abstract
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract
Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer: Implications of the ATAC Trial. Clin Breast Cancer 2003;4(Suppl 1):42-8. Abstract
Chung CT, Carlson RW. The role of aromatase inhibitors in early breast cancer. Curr Treat Options Oncol 2003;4(2):133-40. Abstract
Dowsett M. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol 2003;30(4 Suppl 14):58-69. Abstract
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351(9114):1451-67. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 2003;26(4 Suppl):27-33. Abstract
Ingle JN. Adjuvant endocrine therapy in postmenopausal breast cancer. Clin Cancer Res 2003;9(1 Pt 2):480S-5S. Abstract
Sainsbury R on behalf of the ATAC Trialists' Group. Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: A safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 2002.Abstract 633.
Schmid M et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003;21(6):984-90. Abstract
Winer EP et al. American Society of Clinical Oncology Technology Assessment Working Group Update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003:21(13):2597-9. Abstract
Adjuvant chemotherapy
Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352(9132):930-42. Abstract
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Henderson IC et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract
Robert JM et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc ASCO 2002;Abstract 141.
Watters JM et al. Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer. Ann Oncol 2003;14(12):1744-50. Abstract
|
